- Conditions
- Post-Traumatic Stress Disorders
- Interventions
- Slow Breathing, Meditation, Meditation and slow breathing, Sitting Quietly
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,268
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bipolar Depression
- Interventions
- Deep TMS Treatment, Sham Treatment
- Device
- Lead sponsor
- Brainsway
- Industry
- Eligibility
- 22 Years to 68 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 9
- States / cities
- Juno Beach, Florida • Palm Beach, Florida • Royal Palm Beach, Florida + 6 more
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
- Interventions
- Abaloparatide, Placebo
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years · Male only
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Greenbrae, California • Simi Valley, California + 18 more
- Conditions
- Anesthesia
- Interventions
- Remimazolam, Propofol
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 61
- States / cities
- Muscle Shoals, Alabama • Anchorage, Alaska • Chandler, Arizona + 54 more
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
- Interventions
- IK-930, Osimertinib
- Drug
- Lead sponsor
- Ikena Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 5 more
- Conditions
- Hypertension, Elevated Blood Pressure
- Interventions
- Vascanox® HP
- Dietary Supplement
- Lead sponsor
- Calroy Health Sciences
- Industry
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Interventions
- Setmelanotide
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 12 Months to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 88
- States / cities
- Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Major Depressive Disorder, Suicide, Attempted
- Interventions
- Not listed
- Lead sponsor
- Van Andel Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- Interventions
- AL58805, AL8326, Eribulin, Fulvestrant
- Drug
- Lead sponsor
- Advenchen Pharmaceuticals, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- U-13C-glucose
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey
- Conditions
- Nephrolithiasis
- Interventions
- Novel Nonopioid Pathway
- Other
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Early Detection of Cancer
- Interventions
- Test Performance Information: High Detail, Test Performance Information: Low Detail, Diagnostic Workup Information: High Detail, Diagnostic Workup Information: Low Detail, Test and Workup Cost Information: High Detail, Test and Workup Cost Information: Low Detail
- Behavioral
- Lead sponsor
- Trustees of Dartmouth College
- Other
- Eligibility
- 40 Years to 74 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
- Interventions
- Visual Performance tests, Brain-computer interface
- Diagnostic Test · Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Avelumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 22
- States / cities
- Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more
- Conditions
- Non Small Cell Lung Cancer, Solid Tumor
- Interventions
- BBP-398 with nivolumab
- Drug
- Lead sponsor
- Navire Pharma Inc., a BridgeBio company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Springdale, Arkansas • La Jolla, California • Santa Rosa, California + 11 more
- Conditions
- Osteoarthritis, Knee, Muscle Weakness, Pain, Joint
- Interventions
- PB125, Placebo
- Dietary Supplement
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
- Interventions
- Danicopan, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 17 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
- Conditions
- Spinal Cord Injuries (Complete and Incomplete)
- Interventions
- Multisite transspinal stimulation at rest, Multisite transspinal stimulation during robotic gait training
- Device
- Lead sponsor
- Maria Knikou, PT, MBA, PhD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma, Glioma, Astrocytoma
- Interventions
- LDE225
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more